NPI: 1326040684 · LURAY, VA 22835 · General Acute Care Hospital · NPI assigned 06/01/2005
Authorized official JOHNSON, RENEE controls 20+ related entities in our dataset. Read more
| Authorized Official | JOHNSON, RENEE (CREDENTIALING COORDINATOR) |
| NPI Enumeration Date | 06/01/2005 |
Other providers sharing the same authorized official: JOHNSON, RENEE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 11,735 | $458K |
| 2019 | 24,771 | $1.21M |
| 2020 | 22,713 | $1.58M |
| 2021 | 28,781 | $2.00M |
| 2022 | 33,292 | $2.58M |
| 2023 | 36,817 | $3.12M |
| 2024 | 30,987 | $3.09M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 25,093 | 22,514 | $4.25M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8,922 | 7,788 | $1.88M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 13,201 | 12,066 | $1.82M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,009 | 2,654 | $1.33M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6,497 | 1,833 | $695K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,339 | 2,186 | $534K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,186 | 1,122 | $480K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,420 | 1,336 | $436K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4,072 | 3,864 | $415K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,326 | 981 | $302K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,539 | 3,151 | $242K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 9,493 | 8,928 | $181K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 391 | 370 | $155K |
| 36415 | Collection of venous blood by venipuncture | 8,975 | 7,324 | $154K |
| 97161 | 748 | 729 | $152K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 419 | 398 | $109K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1,284 | 529 | $80K |
| 71046 | Radiologic examination, chest; 2 views | 1,828 | 1,763 | $75K |
| 80053 | Comprehensive metabolic panel | 11,457 | 9,828 | $75K |
| 87428 | 2,653 | 2,541 | $74K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 170 | 136 | $51K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 626 | 521 | $48K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,445 | 1,268 | $34K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 334 | 331 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | 2,944 | 2,789 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4,866 | 2,290 | $26K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,599 | 1,337 | $25K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,534 | 1,435 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12,556 | 10,643 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,740 | 3,340 | $19K |
| 96376 | 263 | 199 | $18K | |
| 81025 | 1,793 | 1,673 | $17K | |
| 73564 | 440 | 400 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,205 | 1,976 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,402 | 2,119 | $14K |
| 73630 | 429 | 394 | $14K | |
| 83880 | 672 | 612 | $13K | |
| 80061 | Lipid panel | 1,312 | 1,257 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,806 | 1,433 | $12K |
| 71045 | Radiologic examination, chest; single view | 3,128 | 2,842 | $11K |
| 73610 | 238 | 226 | $11K | |
| 73030 | 169 | 157 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 479 | 454 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,312 | 1,261 | $9K |
| 85379 | 790 | 702 | $8K | |
| 81002 | 2,413 | 2,320 | $8K | |
| 81003 | 2,743 | 2,545 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 97 | 46 | $7K |
| 85610 | 2,360 | 1,823 | $6K | |
| 81001 | 3,865 | 3,447 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 30 | 29 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,170 | 1,071 | $5K |
| 87634 | 230 | 219 | $4K | |
| 87420 | 172 | 165 | $4K | |
| 84484 | 2,553 | 2,148 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 15 | 15 | $4K |
| 87807 | 394 | 366 | $3K | |
| 80143 | 524 | 461 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 230 | 219 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 416 | 379 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | 74 | 69 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 51 | 51 | $2K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27 | 25 | $2K |
| 73110 | 62 | 57 | $2K | |
| 80306 | 1,540 | 1,384 | $2K | |
| 80179 | 459 | 410 | $1K | |
| 73130 | 67 | 63 | $1K | |
| 87081 | 1,932 | 1,877 | $1K | |
| 83735 | 771 | 647 | $1K | |
| 83690 | 1,605 | 1,450 | $922.27 | |
| 86140 | 151 | 124 | $847.79 | |
| 82607 | 83 | 77 | $827.59 | |
| 84703 | 885 | 818 | $791.58 | |
| 73080 | 16 | 16 | $643.28 | |
| 84439 | 70 | 67 | $633.88 | |
| 82746 | 63 | 59 | $606.92 | |
| 94664 | 166 | 155 | $599.37 | |
| 93000 | 43 | 38 | $524.82 | |
| 84466 | 58 | 50 | $504.47 | |
| 82728 | 30 | 30 | $390.42 | |
| 86803 | 24 | 24 | $340.82 | |
| 85730 | 1,090 | 1,015 | $336.97 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,313 | 1,162 | $295.23 |
| 82947 | 22 | 12 | $294.49 | |
| 85652 | 98 | 88 | $294.25 | |
| 87186 | 441 | 385 | $292.06 | |
| 80050 | General health panel | 15 | 15 | $282.30 |
| 83540 | 58 | 50 | $277.36 | |
| 87040 | 60 | 41 | $242.82 | |
| J7050 | Infusion, normal saline solution, 250 cc | 750 | 350 | $204.14 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 173 | 153 | $133.07 |
| 83605 | 141 | 110 | $120.27 | |
| 85027 | 95 | 95 | $89.16 | |
| 86769 | 19 | 15 | $77.85 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 16 | 12 | $66.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,124 | 1,018 | $61.74 |
| 87077 | 107 | 89 | $50.33 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,246 | 1,173 | $46.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 75 | 54 | $27.70 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 229 | 211 | $27.65 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 361 | 313 | $27.22 |
| J1170 | Injection, hydromorphone, up to 4 mg | 267 | 230 | $23.88 |
| J3490 | Unclassified drugs | 305 | 220 | $23.39 |
| 82948 | 57 | 37 | $12.19 | |
| 82550 | 15 | 12 | $7.93 | |
| 80076 | 15 | 15 | $6.85 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 81 | 79 | $6.68 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 93 | 90 | $5.96 |
| J3535 | Drug administered through a metered dose inhaler | 58 | 55 | $0.00 |
| 94760 | 43 | 41 | $0.00 | |
| 87088 | 12 | 12 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 189 | 181 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 17 | 12 | $0.00 |
| 80047 | 18 | 17 | $0.00 |